BioMarin pares Roctavian spending as it narrows sales focus
Bio Pharma Dive
AUGUST 6, 2024
The company plans to limit sales of the hemophilia gene therapy to the U.S., Italy and Germany, while ending most clinical development work.
Clinical Development Development Sales 
Hookipa partners with Roche for cancer immunotherapy development
Pharmaceutical Technology
OCTOBER 21, 2022
Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.
Development 
278
278 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Acute lymphocytic leukaemia leads in cell therapy clinical development
Pharmaceutical Technology
JULY 12, 2022
The leading marketed CAR-T cell products, Gilead’s Yescarta (axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel), achieved $695m and $587m in sales respectively last year, demonstrating the high potential for sales of successful new cell therapies.
The future of pain medication: are cannabinoids the solution to the opioid epidemic?
Pharmaceutical Technology
JUNE 12, 2023
Accordingly, the development of non-opioid painkillers is experiencing a surge in activity and despite numerous novel targets receiving high levels of attention, cannabinoids have emerged as strong favourites to replace opioid-related medications. On 9 May, National Fentanyl Awareness Day was observed in recognition of the US opioid crisis.
Drugs 358
358 
GSK and Wave Life Sciences partner to develop oligonucleotide therapeutics
Pharmaceutical Technology
DECEMBER 14, 2022
GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes.
Life Science 162
162 
Poseida and Roche to develop cell therapies for hematologic cancers
Pharmaceutical Technology
AUGUST 4, 2022
Poseida Therapeutics and Roche have signed a strategic partnership and licence agreement to develop allogeneic CAR-T cell therapies for hematologic malignancies. Roche and Poseida will also partner in a research programme for creating and developing next-generation features and enhancements for allogeneic CAR-T therapies.
Development 147
147 
Gilead partners with MacroGenics for bispecific antibody development
Pharmaceutical Technology
OCTOBER 18, 2022
Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. Under the deal, the companies will leverage MacroGenics’ DART platform to develop MGD024 as well as two further bispecific research programmes.
Antibody 130
130 
Zerion and Insud to develop Dispersome formulations of drugs
Pharmaceutical Technology
AUGUST 30, 2022
Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.
Development 130
130 
Merck agrees to acquire Imago for $1.35bn
Pharmaceutical Technology
NOVEMBER 21, 2022
A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments. In October this year, Merck reported worldwide sales of $15bn in the third quarter (Q3) of 2022 as against $13.15bn in the year-ago quarter, indicating a rise of 14%.
Clinical Trials 246
246 
Regeneron and CytomX partner to develop bispecific cancer therapies
Pharmaceutical Technology
NOVEMBER 18, 2022
Regeneron Pharmaceuticals has entered a collaboration and licensing agreement with CytomX Therapeutics for developing conditionally-activated bispecific cancer therapies. This collaboration will use Regeneron’s Veloci-Bi bispecific antibody development platform and CytomX's Probody therapeutic platform.
Development 130
130 
Sandoz bulks up ahead of possible sale with Coalesce buy
pharmaphorum
MARCH 14, 2022
This morning, Sandoz announced it has acquired medical and drug delivery device specialist Coalesce Product Development, bolstering its capabilities for the development of respiratory medicines and ‘complex’ generics. The post Sandoz bulks up ahead of possible sale with Coalesce buy appeared first on.
Sales 104
104 
Pfizer and Clear Creek Bio to develop PLpro inhibitors for Covid-19
Pharmaceutical Technology
DECEMBER 7, 2022
Pfizer has entered a research partnership and exclusive licence agreement with Clear Creek Bio to progress new SARS-CoV-2 papain-like protease (PLpro) inhibitors’ discovery and development for the oral treatment of Covid-19. On entering the clinic, Pfizer will solely handle the development and marketing works of the candidate.
Development 130
130 
Lacerta partners with Prevail to develop AAV capsids for CNS diseases
Pharmaceutical Technology
AUGUST 24, 2022
Lacerta Therapeutics has entered a new licensing and research partnership agreement with Eli Lilly and Company subsidiary, Prevail Therapeutics, to discover and develop adeno-associated virus (AAV) capsids for treating central nervous system (CNS) diseases. . Topic sponsors are not involved in the creation of editorial content.
Development 130
130 
GSK to acquire BELLUS Health for $2bn
Pharmaceutical Technology
APRIL 19, 2023
Camlipixant is being assessed in the CALM Phase III clinical development programme, with anticipated regulatory approval and launch in 2026. According to current clinical data, the therapy may reduce cough frequency for RCC patients with a relatively low incidence of dysgeusia by selectively inhibiting P2X3 receptors.
Medicine 243
243 
Betta to commercialise C4 Therapeutics’ CFT8919 in greater China
Pharmaceutical Technology
MAY 31, 2023
C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.
In-Vivo 130
130 
3BP and Novartis strike licensing agreement for FAP-targeting peptide technology
Pharmaceutical Technology
APRIL 25, 2023
3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments. Tiered royalties on net sales are also included in the deal. 3BP continues to hold specific rights to develop its FAP-targeting imaging technology for diagnostic applications.
Licensing 130
130 
Roche Invests $5.3B in Zealand’s Petrelintide, an Obesity Drug Candidate
XTalks
MARCH 17, 2025
Roche, a global leader in biotechnology and diagnostics, has entered into an exclusive collaboration and licensing agreement with Zealand Pharma, a specialist in innovative therapeutics, to co-develop and co-commercialize petrelintide as a potential foundational therapy for people with overweight and obesity. billion $1.4
Hormones 59
59 
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.
Antibody 130
130 
Ono Pharmaceutical enters research deal with Monash University
Pharmaceutical Technology
JANUARY 16, 2023
Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). The collaboration is focused on developing anti-GPCR antibodies, which enable the creation of new treatments for autoimmune and inflammatory diseases.
Research 130
130 
AbbVie and HotSpot sign partnership for autoimmune disease therapy
Pharmaceutical Technology
DECEMBER 7, 2022
The partnership will utilise the Smart Allostery drug discovery platform of HotSpot to develop the first and only small molecule inhibitor of IRF5 for these diseases. HotSpot is also entitled to get option fees and research and development milestone payments totalling up to $295m.
Development 147
147 
Lead Pharma signs $308m deal to develop small molecule drugs with Roche
pharmaphorum
NOVEMBER 17, 2020
Lead Pharma has signed a potential 260 million euro ($308 million) deal with Roche to develop small molecule drugs for immune diseases. Lead will lead the selection of a pre-clinical drug candidate, after which Roche will be responsible for further development and global marketing. The US biotech got $42.5
Development 72
72 
Merck and Orna partner for RNA technology-based vaccines and therapies
Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. Merck will also make royalty payments on any approved products developed out of the partnership.
RNA 147
147 
AbbVie begins trials of COVID-19 antibody therapy
pharmaphorum
DECEMBER 16, 2020
AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.
Antibody 98
98 
China’s NMPA approves Vascepa for hypertriglyceridemia
Pharmaceutical Technology
JUNE 2, 2023
Amarin research and development president and chief scientific officer Dr Steven Ketchum said: “We congratulate our partner, EDDING, on the regulatory approval of Vascepa in Mainland China, as this marks an important step in the process of offering this novel treatment to patients across that country.”
Clinical Trials 130
130 
Vicore signs deal with Alex to develop digital therapeutic to support IPF patients
pharmaphorum
MAY 4, 2021
The agreement allows for a clinical development programme for Vicore’s digital therapeutic (DTx) VP04. million Swedish kroner (around $1 million) plus potential milestone payments and royalties on sales. Vicore has appointed Jessica Shull as head of digital therapeutics to lead the VP04 development programme.
Development 84
84 
Entrance of novel therapies will drive Niemann-Pick type C disease market growth
Pharmaceutical Technology
JULY 26, 2022
This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market. The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%.
Marketing 306
306 
Pfizer acquires ADC pioneer Seagen for $43bn
Pharmaceutical Technology
MARCH 23, 2023
Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.
Licensing 147
147 
Top 10 Largest MedTech Mergers and Acquisitions of the Decade
XTalks
JANUARY 7, 2025
billion Announced : April 2021 Closed : December 2021 Thermo Fisher Scientific, a worldwide supplier of analytical instruments, clinical development solutions, specialty diagnostics, lab, pharmaceutical and biotech services, acquired PPD , a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4
Life Science 105
105 
Capricor and Nippon Shinyaku partner for DMD therapy distribution in Japan
Pharmaceutical Technology
FEBRUARY 17, 2023
Capricor will handle the clinical development of CAP-1002 and sell commercial products to Nippon Shinyaku. Additionally, Capricor will receive up to $89m in further development and sales-based milestones, along with a double-digit share of revenue based on product sales.
Gene Therapy 130
130 
Gilead partners with EVOQ for RA and lupus immunotherapies
Pharmaceutical Technology
JANUARY 4, 2023
Gilead Sciences has entered a collaboration and licensing agreement with EVOQ Therapeutics to advance the latter’s technology and develop immunotherapies to treat rheumatoid arthritis (RA) and lupus. Under the deal terms, the two companies will work together to advance the preclinical development of RA and lupus immunotherapies.
Licensing 130
130 
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
The Pharma Data
MAY 8, 2021
Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Aflibercept is a key treatment in ophthalmology.
Assertio to buy commercial-stage biopharmaceutical firm Spectrum
Pharmaceutical Technology
APRIL 25, 2023
Spectrum is a commercial-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel and targeted oncology treatments. The company has its own clinical development organisation equipped with regulatory and data management competencies.
Syneos Health appoints Michael Brooks as Chief Development Officer
pharmaphorum
JULY 23, 2021
Syneos Health has appointed Michael Brooks as its new chief development officer. In this newly created role, Brooks will lead the company’s customer engagement and market development portfolio. Brooks has more than 25 years of experience within clinical research and commercialisation.
Development 64
64 
Valneva accelerates Lyme disease vaccine R&D project with Pfizer
pharmaphorum
DECEMBER 4, 2020
Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.
Vaccination 119
119 
Verve Therapeutics and Lilly partner to advance gene editing programme
Pharmaceutical Technology
JUNE 15, 2023
Verve Therapeutics will be responsible for advancing the research and development of the Lp(a) programme by completing Phase I clinical development. Lilly will handle the subsequent development, manufacture and commercialisation activities of the programme. Lilly will provide funding for the Phase I clinical trials.
Gene Editing 130
130 
Regeneron, CytomX announce bispecific therapeutics for cancer collab
pharmaphorum
NOVEMBER 18, 2022
Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies. The deal with Regeneron comes months after CytomX Therapeutics laid off 40% of its workers.
Antibody 105
105 
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Retatrutide?
Pharmaceutical Technology
FEBRUARY 24, 2023
Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sales 113
113 
TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis
BioTech 365
SEPTEMBER 22, 2020
TPG Capital establishes new entity to continue the development of select clinical assets spun-out of Adare Pharmaceuticals Announcement follows TPG Capital’s sale of Adare Pharmaceuticals’ specialty CDMO pharmaceutical technology and microbiome businesses SAN FRANCISCO & FORT WORTH, Texas–(BUSINESS WIRE)–TPG Capital, … (..)
Rezvilutamide by Jiangsu Hengrui Medicine for Liver Failure (Hepatic Insufficiency): Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Medicine 100
100 
Rezvilutamide by Jiangsu Hengrui Medicine for Prostate Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here.
Medicine 100
100 
Orvacabtagene autoleucel by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Pharmaceutical Technology
MARCH 1, 2023
Orvacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Pharmacy 100
100 
Risk adjusted net present value: What is the current valuation of Axsome Therapeutics’s Esreboxetine?
Pharmaceutical Technology
FEBRUARY 20, 2023
Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sales 100
100 
Danicamtiv, what is the likelihood that the drug will be approved?
Pharmaceutical Technology
JANUARY 2, 2023
Danicamtiv is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. Danicamtiv overview Danicamtiv (MYK-491, DCM-1) is under development for the treatment of dilated cardiomyopathy (DCM), atrial fibrillation and systolic heart failure.
Drugs 100
100 
Setanaxib by Calliditas Therapeutics for Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Likelihood of Approval
Pharmaceutical Technology
MAY 31, 2023
Setanaxib is under clinical development by Calliditas Therapeutics and currently in Phase III for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Clinical Trials 100
100 
Let's personalize your content